anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cosmetic formulations comprising hypoallergenic peanut flour are disclosed. The hypoallergenic peanut flour is used for its abrasive or rheological/viscosity modifying properties, or as a filler. The cosmetics can be in the form of emulsions, dry powders, and the like. The hypoallergenic peanut flour can be formed in any suitable way. In one embodiment, the hypoallergenic peanut flour is formed by reacting raw, blanched, and/or roasted peanuts and/or peanut pieces with enzymes such as endo and exopeptidases, and optionally also with ultrasound, then converting the enzyme-treated peanuts into peanut flour. In another embodiment, the hypoallergenic peanut flour is formed by reacting raw, blanched, and/or roasted peanut flour with enzymes such as endo and exopeptidases, and optionally also with ultrasound.
OBJECTIVE: The purpose of this paper is to call for a nationwide study to assess the prevalence and incidence of women health problems related to menstrual disorders and severe pelvic pain.
RATIONALE: The exact prevalence and incidence of endometriosis, adenomyosis, severe painful menstrual disorders, and of severe chronic pelvic pain are unknown. These issues severely impact women's quality of life and represent huge costs for our societies. Using adapted questionnaires, recent progresses in diagnosis and increased fundings announced by politicians, we can and should change this situation by performing a nationwide study to assess prevalence and incidence of these women problems in the French general population. The huge, anticipated costs of this study do appear quite reasonable when accounting for the enormous costs and societal consequences of endometriosis, menstrual disorders and severe pelvic pain.
CONCLUSION: These long-awaited data will improve our understanding of the causes, consequences, and natural history of endometriosis. These data will allow women to better understand that pain is not always related to endometriosis, thus preventing unjustified fears. Physicians will be able to adapt and improve medical managements, particularly the diagnosis. Politicians will have the tools to improve women's health and gender equality.
Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
During treatment period 2, subjects will receive EM 1 mg (Medisca) and 5-HTP 100 mg (5-HTP, Basic Vitamins). One of each capsule (both size 00) will be taken three times per day for four weeks.
PROBLEM TO BE SOLVED: To obtain a sheet-like cataplasm capable of being repeatedly adhered or peeled and further capable of being suitably stored on the aspect of sanitarians by disposing a specific layer on a contact surface with an adhesive layer. SOLUTION: This sheet-like cataplasm has a peeling layer on an adhesive layer comprising a wet adhesive composition, wherein the contact surface of the peeling layer with the adhesive layer is treated with a peeling agent. The peeling layer used herein includes a plastic film such as a polyester film or a metal film such as an aluminum foil. The peeling agent is preferably a silicone material represented by, e.g. dimethylpolysiloxane. The wet adhesive composition preferably comprises (A) polyvinyl pyrrolidone and/or a vinyl pyrrolidone.vinyl acetate copolymer, (B) a liquid plasticizer compatible with the component A, and (C) a filler. The adhesivity of the adhesive layer in the cataplasm can be enhanced by controlling the water content or liquid component content of the adhesive layer.
Across systems, higher-order interactions between components govern emergent dynamics. Here we tested whether contextual threat memory retrieval in mice relies on higher-order interactions between dorsal CA1 hippocampal neurons requiring learning-induced dendritic spine plasticity. We compared population-level Ca2+ transients as wild-type mice (with intact learning-induced spine plasticity and memory) and amnestic mice (TgCRND8 mice with high levels of amyloid-β and deficits in learning-induced spine plasticity and memory) were tested for memory. Using machine-learning classifiers with different capacities to use input data with complex interactions, our findings indicate complex neuronal interactions in the memory representation of wild-type, but not amnestic, mice. Moreover, a peptide that partially restored learning-induced spine plasticity also restored the statistical complexity of the memory representation and memory behavior in Tg mice. These findings provide a previously missing bridge between levels of analysis in memory research, linking receptors, spines, higher-order neuronal dynamics and behavior.
PURPOSE: A rheumatic or arthritic disorder treating composition which contains sphingosine 1-phosphate is provided to suppress various inflammatory factors. CONSTITUTION: A rheumatic or arthritic disorder treating composition comprises pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. An inflammatory inducer is cyclooxygenase-2, inducible nitric oxide synthesis or NFkB(nuclear factor kB). The composition suppressing the chondrocyte inflammation contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. The composition for treating the rheumatic or arthritic disorder contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. The rheumatic or arthritic disorder is rheumatoid arthritis, degenerative arthritis, ankylosing spondylitis or osteoporosis. The composition which obstructs the inflammatory inducer contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients.
The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
An axial length control agent comprising a TGF-.beta. regulating substance as an active ingredient.  More particularly, an axial elongation inhibitor comprising a TGF-.beta. activator, specifically a plasminogen activator, as an active ingredient, which is an agent for the prophylaxis and treatment of myopia.  An axial elongation agent comprising a TGF-.beta. activation inhibitor, particularly a plasminogen activator inhibitor, as an active ingredient, which is an agent for the prophylaxis and treatment of myopia.  In addition, a commercial package comprising any one of the above-mentioned axial length inhibitors and a written indicating the use thereof.  The axial length control agent of the present invention controls elongation of the axial length, and is extremely useful for the prophylaxis and treatment of myopia or hyperopia.  It is also useful for preparing experimental model animals having eyes with complete axial myopia or hyperopia exclusive of refractive myopia or hyperpia.
Old age is a physiological period of life in which various changes take place, meaning that the elderly must be given special consideration as a group with regard to health care. Advancing age arising changes in health status and systems adversely affect the quality of life of the elderly and the elderly face many complex health problems. Constipation is one of the common problems in the elderly. Insufficient liquid intake, insufficient or unsuitable diet, decreased mobility, the side effects of medication, underlying diseases, and rectal sensory-motor dysfunction are among the causes of constipation in the elderly. Constipation is a preventable and treatable problem, which if left untreated can cause physical and associated psychological problems such as back and waist pain, rectal pressure, loss of appetite, confusion, incontinence, nausea and vomiting, urinary dysfunction, fissure, rectal prolapse, hemorrhoids, intestinal obstruction, and syncope. Constipation can be managed using pharmacological methods, such as laxatives, enemas, suppositories, along with nonpharmacological procedures, such as changes in nutritional habits, fluid intake, education, activities to develop healthy intestinal habits, exercise, massage, aroma massage, biofeedback, stress management and acupuncture.
To observe the efficacy of topical antipruritic spray (TAS) in the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase-related rashes, and to evaluate its efficacy and safety. 120 malignant tumor patients with confirmed pathological diagnosis and rash after EGFR application were selected and randomly divided into an experimental group of 60 cases and a control group of 60 cases. The 2 groups were intervened with self-made antipruritic spray and erythromycin ointment for 14 consecutive days. To observe the changes in rash, itching degree, and quality of life index of skin diseases in both groups of patients before and after treatment. The decrease in the number of itching cases in the experimental group reached 53.84%, and after 7 weeks of intervention, the total effective rate of rash treatment in this group of patients (91.67%) was significantly better than that in the control group (36.67%); The symptoms of the dermatology life quality index (DLQI) scale in the experimental group patient table after intervention showed significant changes compared to before intervention. After statistical testing, there was a significant difference between the groups and outside the group (R < 0.05). And the comprehensive effect of the experimental patients with external spray after 14 weeks of intervention reached 93.16%. The self-made antipruritic spray has significant effect on improving EGFR rash and itching, and there is no obvious adverse reaction.
PURPOSE:To obtain a make-up cosmetic having high strength, excellent sliding properties, slip and spreadability, forming a cosmetic film not in a powdery state, having a new feeling in use, being readily shaded off without causing unevenness by combining gypsum with powder for cosmetic and a degrading agent. CONSTITUTION:Mixed powder containing 10-50wt.% of gypsum, 20-80wt.% of powder for cosmetic and 5-35wt.% of a degrading agent is dispersed into water or a mixed solution of water and additives (oil agent, surfactant, gelatinizing agent, polyhydric alcohol, etc.) to give a slurry. Then the slurry is packed, molded, dried and solidified to give a make-up cosmetic. The make-up cosmetic is especially preferably in a solid powder state. The gypsum is anhydrous gypsum or hemihydrate of the formula CaSO4 and/ or CaSO4.1/2H2O. The powder for cosmetic, for example, is tale, kaolin, mica, titanium oxide, etc. The degrading agent is added so as to provide sliding properties in use. For example, nylon powder, silicone powder or styrene powder may be cited as the degrading agent.
Trained instructors will provide the Health and Wellness Curriculum at the Ravenswood City schools. Each school receiving the curriculum will have a dedicated space and receive a 30 minute class twice a week. Through group discussion, nutrition and character education, and breathing exercises, students will receive instruction to focus their attention, calm their minds, reduce stress, and think before reacting.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to derivatives of imidazole of the formula (I)   where Y is H, phenyl, phenylalkyl, pyridyl, pyridylalkyl; Ar 1  and Ar 2  are phenylene; X and X 1  are O, S, SO or SO 2 ; R 1  is H or alkyl; R 2  and R 3  are methylene, ethylene or propylene. Synthesized compounds show capacity to inhibit enzyme lipoxygenase. Compounds of the formula (I) can be used for treatment of patients with bronchial asthma, skin diseases and arthritis in mammals. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 9 cl, 51 ex
The present invention relates to a method for preparing a Chinese medicinal herbal preparation for treating cardiovascular/cerebrovascular diseases. The present invention overcomes the defects of complicated synthesis process, poor curative effect, high cost and compound medicine with toxic side effect in the prior art. The present invention is characterized in that the present invention is realized by that Chinese herbal medicines, such as red sage roots, flores carthami, astragalus roots, bezoars, musk, earthworms, SCORPIO, hirudo, siegesbeckia pubescens mak and peach kernels are ground into powder. The Chinese medicinal herbal preparation adopts pollution-free pure natural Chinese herbal medicines in the Yunnan-Kweichow Plateau as raw materials, and is prepared by combining the compatible theory of traditional Chinese medicines. Thus, the Chinese medicinal herbal preparation has the functions of strengthening the body resistance, expelling blood stasis, dredging the meridian passages, eliminating phlegm for resuscitation, nourishing blood and promoting blood circulation, is used for treating various cardiovascular/cerebrovascular diseases, and has good curative effect and no toxic side effect. The present invention can be used for preparing medicines for treating cardiovascular/cerebrovascular diseases.
BACKGROUND: Psoroptic mange, caused by Psoroptes ovis mites, is affecting Belgian Blue cattle's welfare and production potential. The Belgian Blue cattle-known for its high degree of muscling, low feed conversion ratio and high beef quality-is highly susceptible for this disease.
RESULTS: In this study, we phenotyped 1975 Belgian Blue cattle from more than 100 different groups on commercial beef farms for their psoroptic mange susceptibility. Substantial individual differences were observed within these management groups, with lesion extent differences up to ± 15%. Animal models showed that estimated heritabilities were low for lesion extent and severe lesion extent (0.07 and 0.09, respectively) and 0.12 for the number of mites. A genome wide association study for mange susceptibility revealed signals on BTA6, BTA11, BTA15 and BTA24. In these regions, candidate genes GBA3, RAG2, and TRAF6 were identified.
CONCLUSIONS: Despite the challenges in phenotyping for psoroptic mange due to the timing of screening, the continuous evolution of lesions and different management conditions, we successfully conducted a study on the genetic susceptibility to psoroptic mange in Belgian Blue cattle. Our results clearly indicate that psoroptic mange is under polygenic control and the underlying candidate genes should be studied more thoroughly. This is the first study providing candidate genes for this complex disease. These results are already valuable for Belgian Blue breeding, however, further research is needed to unravel the architecture of this disease and to identify causal mutations.
Lung ultrasound (LUS) has recently gained popularity among the imaging methods to perform bedside assessment of critically ill patients to guide clinical management. LUS is a non-invasive and easy-to-perform procedure that provides precise data on lung aeration, lung recruitment, lung morphology, and lung perfusion. Studies have shown that LUS is a useful tool in monitoring lung reaeration in intubated patients diagnosed with traditional ARDS undergoing prone positioning; however there are mixed findings in terms of the use of LUS in predicting potential prone positioning response. A recent study found that the non-intubated COVID-19 patients who responded to prone positioning had more pronounced disturbances of aeration in posterior regions, however, they only investigated patients' response to the first prone positioning and the information for the patients' outcome is lacking. In our previous study with intubated COVID-19 patients, we found that patients' response to the subsequent prone positioning had higher predictive value than the response to the first prone positioning. Therefore, the primary objective of this study is to explore the physiological mechanism of awake, self proning among patients with acute hypoxemic respiratory failure induced by COVID-19, using LUS in the first three days and explore the predictive value of LUS in patients' outcome.
PURPOSES: To probe the expression, clinical significance, roles, and molecular mechanisms of circRNA_000166 in breast cancer (BC).
METHODS: Clinical tissue samples were gathered from 84 BC patients who underwent surgery at the Affiliated Hospital of Chengde Medical College. Clinical data were obtained from medical records and postoperative follow-up. Expression levels of circRNA_000166, miR-326, miR-330-5p, and ELK1 mRNA in BC tissues and cells were measured by qRT-PCR, and ELK1 protein levels were assessed by WB. Pearson's correlation analysis evaluated the interrelationships between these RNAs in clinical samples. Luciferase reporter assays verified the interactions between miR-326/miR-330-5p and circRNA_000166, as well as between miR-326/miR-330-5p and ELK1. Cell proliferation, migration, and apoptosis were examined using CCK-8, colony formation, transwell, and flow cytometry assays, respectively.
RESULTS: CircRNA_000166 was highly expressed in BC tissues and inversely correlated with miR-326/miR-330-5p levels but positively with ELK1 mRNA levels. ELK1 mRNA also inversely associated with miR-326/miR-330-5p levels in BC tissues. Importantly, our findings demonstrated that circRNA_000166 targets miR-326 and miR-330-5p, while ELK1 is the target of miR-326 and miR-330-5p in BC cells. CircRNA_000166 levels positively correlated with tumour size, TNM stage, histological grade, and lymph node metastasis, and negatively associated with postoperative progression-free survival (PFS) and overall survival (OS) in BC patients. CircRNA_000166 was also highly expressed in BC cells, and knockdown of circRNA_000166 reduced proliferation and migration, and increased apoptosis via miR-326/ELK1 and miR-330-5p/ELK1 pathways in vitro.
CONCLUSION: CircRNA_000166 enhances BC progression through miR-326/ELK1 and miR-330-5p/ELK1 pathways and shows potential as a biomarker for BC diagnosis and treatment.
A pharmaceutical compsn. having synergistic effect comprises as active ingredients sulbactam of its pharmaceutically acceptable salts or piperacillin or its pharmaceutically acceptable salts. The compsn. exhibits synergistic effect which is much more greater than the sum of antibacterial effect of each component alone. The compsn. is active against bacteria resistant to conventional penicillines. The compsn. can be used as injections or for oral use and the active ingredients are admixed in a ratio of 1:99 to 99:1.
INTRODUCTION: The use of magnetic resonance imaging (MRI) with a magnetic intramedullary lengthening nail in place is contraindicated per the manufacturer due to the concern of implant activation and migration. A prior in vitro study did not confirm these complications only noting that a 3.0 T MRI weakened the internal magnet. Therefore, a retrospective analysis of patients who underwent an MRI with a magnetic nail in place was performed to determine if any adverse effects occurred in the clinical setting.
MATERIALS AND METHODS: A retrospective review of all patients who underwent an MRI with a magnetic lengthening nail in place was performed. The time spent being imaged in the MRI, number of times the patient entered the MRI suite, and the images obtained were recorded. Radiographs were performed before and after the MRI to determine if any hardware complications occurred. The patients were monitored for any adverse symptoms while they were in the suite.
RESULTS: A total of 12 patients with 13 nails were identified. Two patients underwent imaging with a 3.0 T MRI while the remaining 10 underwent imaging with a 1.5 T MRI. Each patient entered the MRI suite 2.1 times and spent an average of 84.7 min being imaged in the MRI (range 21-494). No patients noted any adverse symptoms related to the nail while in the suite and no hardware complications were identified.
CONCLUSION: MRI appears to be safe with a magnetic nail in place and did not result in any complications. Given the manufacturer's recommendations, informed consent should be obtained prior to an MRI being performed and a 3.0 T MRI should be avoided when possible if further activation of the nail is required.
As HARVONI contains ledipasvir and sofosbuvir, any interactions that have been identified with these agents individually may occur with HARVONI.

After oral administration of HARVONI, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction. In clinical pharmacology studies, both sofosbuvir and the inactive metabolite GS-331007 were monitored for purposes of pharmacokinetic analyses.

Ledipasvir is an inhibitor of the drug transporters P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for these transporters.

Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not. P-gp inducers (e.g., rifampin, St. John's wort) may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of HARVONI, and the use with P-gp inducers is not recommended with HARVONI [see Warnings and Precautions (5.3)].
The invention particularly relates to a traditional Chinese medicine liniment for treating epichrosis leucasmus and armpit odor. The effective ingredient of the liniment come from the traditional Chinese medicines in following weight parts: 1-6 parts of arsenic sulphide, 1-6 parts of sulfur, 1-6 parts of litharge, 1-3 parts of hydrargyri subchloridum, 1-9 parts of fructus cnidii, 1-6 parts of honeycomb, 1-15 parts of fructus psoraleae, 1-9 parts of radix aconiti carmichaeli, 1-9 parts of aconitum chinese paxton, 1-9 parts of hurricane lamp and 1-9 parts of trumpet creeper. A preparation methodof the liniment is simple and only comprises following steps: grinding the medicines in a recipe into fine powder, and then adding alcohol or vinegar the weight of which is 8-15 times of the medicinepowder to soak the medicine powder for 2-7 days. The medicines in the recipe are combined, enabling the prepared liniment to have the efficiencies of dispelling wind and arresting itching, detoxicating and destroy intestinal worms, eliminating dampness and astricting tumefaction, resuscitating and removing dirt, activating blood flow and removing blood stasis, disintegrating mass and eliminatingpus and the like. Through clinical verification, the liniment is used for treating epichrosis leucasmus, and the effectual rate reaches as high as 100%. The liniment can effectively restrain armpit odor and can thoroughly treat armpit odor after being used for a long time.